Enhances regenerative medicine CDMO capabilities and expands differentiated portfolio of allograft and xenograft biomaterials.
RTI Surgical, an industry-leading contract development and manufacturing organization (CDMO) serving the regenerative medicine industry, announced today that it has completed its previously announced acquisition of Cook Biotech Incorporated. The combined entity is the only regenerative medicine company that offers a differentiated portfolio of allograft and xenograft biomaterials at scale.
“We are excited to welcome the Cook Biotech team and leverage our unmatched expertise in soft tissue to enhance patients’ lives and outcomes,” said Olivier Visa, RTI Surgical President and Chief Executive Officer. “We are proud to offer customers and surgeons an innovative, clinically proven portfolio of differentiated allograft and xenograft biomaterials to better address the unique needs of individual patients.”
The company will provide customers with leading-edge expertise, scale and flexibility across end-to-end services including design, development, regulatory support, verification and validation, manufacturing and supply chain management. RTI will also enter new markets and expand its offerings to new clinical segments with Cook Biotech’s porcine small intestinal submucosa (SIS) platform.
RTI’s acquisition of Cook Biotech is backed by its main shareholder Montagu, who is increasing its investment in the group and contributing carve-out experience and capabilities to the transaction. Adrien Sassi, partner at Montagu, said: “This acquisition reinforces RTI’s strategic focus on soft tissue clinical segments and we are excited to support them in reaching their full potential during this next phase of development.”